{"entity":{"id":"nct03815643","kind":"trial","name":"Avelumab Program Rollover Study","aka":[],"tldr":"A phase 3 trial of Avelumab in advanced solid tumours, run by EMD Serono Research & Development Institute, Inc., active and no longer recruiting.","summary":"Avelumab Program Rollover Study is a phase 3 interventional study registered as NCT03815643 by EMD Serono Research & Development Institute, Inc., with 205 participants enrolled, started 2019-03-22 and due to reach its primary completion in 2026-08-21. Interventions recorded: Avelumab.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT03815643","url":"https://clinicaltrials.gov/study/NCT03815643"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":["avelumab"],"companies":["merck-kgaa"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT03815643","phase":"3","setting":"An Open-Label, Multicenter Follow-up Study to Collect Long-term Data on Participants From Multiple Avelumab (MSB0010718C) Clinical Studies","sponsor":"EMD Serono Research & Development Institute, Inc.","enrolled":205,"outcomes":[]},"route":"/trials/nct03815643/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"drug":[{"id":"avelumab","kind":"drug","name":"Avelumab","route":"/drugs/avelumab/"}],"company":[{"id":"merck-kgaa","kind":"company","name":"Merck KGaA (EMD Serono)","route":"/companies/merck-kgaa/"}]}}